Amgen Inc.

Amgen owns a robust portfolio of biologics including Enbrel and biosimilars like ABP 959. Their infrastructure includes significant manufacturing capabilities and a strong presence in PBM contracting, which allows them to offer competitive pricing on key drugs.

Amgen collaborates with Samsung Bioepis on biosimilar development, exemplified by ABP 654. They also have a strategic acquisition of Horizon Therapeutics, which expands their rare disease pipeline and leverages Horizon's existing market access.

Upcoming launches include biosimilars like ABP 654 targeting Stelara, and ABP 959 challenging Soliris. The Horizon acquisition is expected to bolster their rare disease offerings, although specific assets from Horizon have yet to be detailed.

Amgen is a heavyweight in the biosimilar space, competing with Sandoz, Pfizer, and Biocon. They maintain a strong position with Enbrel despite pricing pressures, but the looming entry of biosimilars presents ongoing challenges.

Amgen is forward-looking with significant investment in biosimilar technology and manufacturing efficiency. However, there is limited insight into their adoption of AI or advanced data platforms beyond standard industry practices.

Amgen is on a steady growth trajectory, driven by strategic acquisitions like Horizon and expanding biosimilar portfolios. However, the pressure from biosimilar competition requires continuous innovation and market adaptation.